Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Viridian Therapeutics, Inc.\DE (VRDN) Other Accumulated Expenses: 2014-2018

Historic Other Accumulated Expenses for Viridian Therapeutics, Inc.\DE (VRDN) over the last 4 years, with Dec 2018 value amounting to $174,000.

  • Viridian Therapeutics, Inc.\DE's Other Accumulated Expenses was N/A to $113,000 in Q1 2019 from the same period last year, while for Mar 2019 it was $113,000, marking a year-over-year change of. This contributed to the annual value of $174,000 for FY2018, which is N/A change from last year.
  • As of FY2018, Viridian Therapeutics, Inc.\DE's Other Accumulated Expenses stood at $174,000, which was up 17.57% from $148,000 recorded in FY2016.
  • In the past 5 years, Viridian Therapeutics, Inc.\DE's Other Accumulated Expenses registered a high of $174,000 during FY2018, and its lowest value of $80,000 during FY2014.
  • Its 2-year average for Other Accumulated Expenses is $161,000, with a median of $161,000 in 2016.
  • Data for Viridian Therapeutics, Inc.\DE's Other Accumulated Expenses shows a peak YoY surged of 43.69% (in 2016) over the last 5 years.
  • Yearly analysis of 4 years shows Viridian Therapeutics, Inc.\DE's Other Accumulated Expenses stood at $80,000 in 2014, then rose by 28.75% to $103,000 in 2015, then surged by 43.69% to $148,000 in 2016, then reached $174,000 in 2018.